Guidelines for the management of oesophageal and gastric cancer

WH Allum, JM Blazeby, SM Griffin, D Cunningham… - Gut, 2011 - gut.bmj.com
STRUCTURE OF THE GUIDELINES The original guidelines described the management of
oesophageal and gastric cancer within existing practice. This paper updates the guidance to …

Chemotherapy for advanced gastric cancer

AD Wagner, NLX Syn, M Moehler… - Cochrane database …, 2017 - cochranelibrary.com
Background Gastric cancer is the fifth most common cancer worldwide. In" Western"
countries, most people are either diagnosed at an advanced stage, or develop a relapse …

Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology

JA Ajani, TA D'Amico, DJ Bentrem, J Chao… - Journal of the National …, 2022 - jnccn.org
Gastric cancer is the third leading cause of cancer-related deaths worldwide. Over 95% of
gastric cancers are adenocarcinomas, which are typically classified based on anatomic …

Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE …

K Shitara, E Van Cutsem, YJ Bang, C Fuchs… - JAMA …, 2020 - jamanetwork.com
Importance Safe and effective therapies for untreated, advanced gastric/gastroesophageal
junction (G/GEJ) cancer remain an unmet need. Objective To evaluate the antitumor activity …

Gastric cancer, version 3.2016, NCCN clinical practice guidelines in oncology

JA Ajani, TA D'Amico, K Almhanna, DJ Bentrem… - Journal of the National …, 2016 - jnccn.org
Gastric cancer is the fifth most frequently diagnosed cancer and the third leading cause of
death from cancer in the world. Several advances have been made in the staging …

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult …

MS Aapro, J Bohlius, DA Cameron, L Dal Lago… - European journal of …, 2011 - Elsevier
Chemotherapy-induced neutropaenia is a major risk factor for infection-related morbidity
and mortality and also a significant dose-limiting toxicity in cancer treatment. Patients …

[HTML][HTML] Peritoneal carcinomatosis

F Coccolini, F Gheza, M Lotti, S Virzì… - World journal of …, 2013 - ncbi.nlm.nih.gov
Several gastrointestinal and gynecological malignancies have the potential to disseminate
and grow in the peritoneal cavity. The occurrence of peritoneal carcinomatosis (PC) has …

CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent …

AE Slagter, EPM Jansen, HWM van Laarhoven… - Bmc Cancer, 2018 - Springer
Background Although radical surgery remains the cornerstone of cure in resectable gastric
cancer, survival remains poor. Current evidence-based (neo) adjuvant strategies have …

Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials

F Coccolini, E Cotte, O Glehen, M Lotti… - European Journal of …, 2014 - Elsevier
Introduction An important component of treatment failure in gastric cancer (GC) is cancer
dissemination within the peritoneal cavity and nodal metastasis. Intraperitoneal …

Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric …

U Rudloff, RC Langan, JE Mullinax… - Journal of surgical …, 2014 - Wiley Online Library
Background A prospective randomized trial was conducted to compare the impact of
systemic chemotherapy versus multi‐modality therapy (complete cytoreductive surgery …